Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Memorial Sloan-Kettering Cancer Center National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00004922 |
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have advanced neuroendocrine tumors.
Condition | Intervention | Phase |
---|---|---|
Carcinoma of Unknown Primary Neuroendocrine Carcinoma Neuroendocrine Carcinoma of the Skin |
Drug: irinotecan hydrochloride |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase II Clinical Trial of Irinotecan (CPT-11) in Patients With Advanced High Grade Neuroendocrine Tumors |
Study Start Date: | June 1999 |
OBJECTIVES:
OUTLINE: Patients receive irinotecan IV over 90 minutes once weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed until death.
PROJECTED ACCRUAL: A total of 10-31 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically proven metastatic or unresectable high grade neuroendocrine tumor including:
High grade tumor indicated by at least one of the following:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
United States, New York | |
Memorial Sloan-Kettering Cancer Center | |
New York, New York, United States, 10021 |
Study Chair: | Sunil Sharma, MD | Memorial Sloan-Kettering Cancer Center |
Study ID Numbers: | CDR0000067605, MSKCC-99041, NCI-G00-1683 |
Study First Received: | March 7, 2000 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00004922 History of Changes |
Health Authority: | United States: Federal Government |
newly diagnosed carcinoma of unknown primary recurrent carcinoma of unknown primary stage III neuroendocrine carcinoma of the skin recurrent neuroendocrine carcinoma of the skin neuroendocrine carcinoma |
Neoplasms, Unknown Primary Skin Diseases Carcinoma, Neuroendocrine Carcinoma, Basosquamous Irinotecan Carcinoma, Basal Cell Skin Neoplasms Camptothecin Recurrence Carcinoma Neuroendocrine Tumors |
Carcinoma, Merkel Cell Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasm Metastasis Neuroepithelioma Neoplasms, Basal Cell Neoplasms, Squamous Cell Adenocarcinoma Carcinoma, Squamous Cell Antineoplastic Agents, Phytogenic Neoplasms, Glandular and Epithelial |
Molecular Mechanisms of Pharmacological Action Carcinoma, Basosquamous Carcinoma, Neuroendocrine Antineoplastic Agents Neoplasms, Nerve Tissue Irinotecan Neoplastic Processes Pathologic Processes Neoplasms by Site Therapeutic Uses Neoplasms, Germ Cell and Embryonal Neoplasm Metastasis Neoplasms, Basal Cell Neoplasms, Squamous Cell Neoplasms, Unknown Primary |
Neoplasms by Histologic Type Skin Diseases Enzyme Inhibitors Carcinoma, Basal Cell Skin Neoplasms Pharmacologic Actions Camptothecin Neuroendocrine Tumors Carcinoma Carcinoma, Merkel Cell Neuroectodermal Tumors Neoplasms Carcinoma, Squamous Cell Adenocarcinoma Antineoplastic Agents, Phytogenic |